| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/10/2002 | CA2413245A1 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412836A1 Peptide composition for treatment of periodontal diseases and prevention of skin aging |
| 01/10/2002 | CA2412775A1 Antibodies to human mcp-1 |
| 01/10/2002 | CA2412287A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/10/2002 | CA2410945A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170594A2 Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2 |
| 01/09/2002 | EP1170015A1 Use of extracts of the fungus Grifola frondosa |
| 01/09/2002 | EP1170013A1 Drugs, foods, drinks and feeds containing cocoa component |
| 01/09/2002 | EP1169469A1 Human colon cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169353A1 Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor |
| 01/09/2002 | EP1169348A1 Purposeful movement of human migratory cells away from an agent source |
| 01/09/2002 | EP1169346A1 48 human secreted proteins |
| 01/09/2002 | EP1169344A1 47 human secreted proteins |
| 01/09/2002 | EP1169343A2 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof |
| 01/09/2002 | EP1169338A2 Low-molecular inhibitors of complement proteases |
| 01/09/2002 | EP1169337A2 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction |
| 01/09/2002 | EP1169334A1 48 human secreted proteins |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169317A1 Triarylimidazoles |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169302A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 01/09/2002 | EP1169301A1 A topical antiandrogen for hair loss and other hyperandrogenic conditions |
| 01/09/2002 | EP1169300A1 Compounds derived from benzoic acid esters, composition containing said compounds and use thereof |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169082A1 Method of providing cosmetic/medical therapy |
| 01/09/2002 | EP1169058A1 Insulin-like growth factor binding protein-4 protease |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP1168917A2 Human lung cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP0765151B1 Antibacterial oil-in-water emulsions |
| 01/09/2002 | CN1330664A Platelet-derived growth factor C, DNA coding therefor and uses thereof |
| 01/09/2002 | CN1330661A Procollagen C-proteinase inhibitors |
| 01/09/2002 | CN1330655A Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 01/09/2002 | CN1330642A N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |
| 01/09/2002 | CN1330631A Amide derivatives which are useful as cell factor inhibitors |
| 01/09/2002 | CN1330555A Antibodies to truncated VEGF-D and uses thereof |
| 01/09/2002 | CN1330550A Use of substances with oxytocin activity in order to create cell regeneration |
| 01/09/2002 | CN1330545A Treating for skin disease |
| 01/09/2002 | CN1330539A Compositions and methods for treatment of anorectal disorders |
| 01/09/2002 | CN1330532A Oil-in-water emulsion comprising micronised biologically active agent and appropriate emulsified system |
| 01/09/2002 | CN1329914A Hair generating pill |
| 01/09/2002 | CN1329906A Clots dispersing medicine 'Huayudan' |
| 01/09/2002 | CN1329904A Process for preparing arnebia root medicine with broad-spectrum medical functions |
| 01/09/2002 | CN1329903A Medicine for treating acne |
| 01/09/2002 | CN1329894A Medicine for treating wart with anti-inflammatino detoxication |
| 01/09/2002 | CN1329891A Vascular formation inhibitor |
| 01/09/2002 | CN1077432C Medicine for treating haemorrhoids |
| 01/09/2002 | CN1077427C Skin protecting composition containing acid hydrophilic agent for cosmetic use and application of same |
| 01/09/2002 | CN1077424C Shampoo containing gypsophila extract and its prducing technique |
| 01/08/2002 | US6337411 Muscular disorders |
| 01/08/2002 | US6337325 Combined preparation for the therapy of immune diseases |
| 01/08/2002 | US6337318 Drugs for peptide agonist |
| 01/08/2002 | US6337077 Composition with a continuous aqueous phase containing L-2-oxothiazolidine-4-carboxylic acid |
| 01/08/2002 | US6337076 Applying onto hypertrophic scar a liquid formulation comprising collodion film-forming carrier having dermatologically effective amount of active ingredient capable of reducing size of scar or improving appearance |
| 01/08/2002 | US6337065 For therapy of disorders such as sunburn and other skin deterioration that results from dna damage in skin cells |
| 01/08/2002 | CA2193087C Topical compositions comprising n-acetyl-l-cysteine |
| 01/03/2002 | WO2002000892A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| 01/03/2002 | WO2002000877A2 Antisense oligonucleotides to inhibit angiogenesis and/or metastasis |
| 01/03/2002 | WO2002000876A1 Truncated egf receptor |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000840A2 Human lyases |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000632A1 Benzodiazepines as inhibitors of hpv e1 helicase |
| 01/03/2002 | WO2002000631A2 Benzhydryl derivatives |
| 01/03/2002 | WO2002000630A1 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 01/03/2002 | WO2002000611A2 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | WO2002000269A1 The use of honey in wound dressings |
| 01/03/2002 | WO2002000268A1 Sprayable wound care compositions |
| 01/03/2002 | WO2002000244A2 Protein mixtures for wound healing |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000214A1 Flavone/flavanone derivatives for the systemic treatment and prophylaxis of uv-induced dermatoses |
| 01/03/2002 | WO2002000203A1 Topical pharmaceutical formulations and methods of treatment |
| 01/03/2002 | WO2002000195A2 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | WO2002000190A1 Cosmetic and pharmaceutical compositions and methods using green-light emitting materials |
| 01/03/2002 | WO2002000189A1 Cosmetic treatment and device |
| 01/03/2002 | WO2002000188A1 Use of inulin and inulin derivatives |
| 01/03/2002 | WO2002000187A1 Use of inulins and inulin derivatives |
| 01/03/2002 | WO2002000183A2 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000142A2 Intervertebral disc |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001066601A8 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/03/2002 | WO2001066544A3 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 01/03/2002 | WO2001066076A3 Echinacea extract as anti-irritant and anti-aging booster in cosmetic compositions |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |